Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;32(12):25-29.

Treatment Failure With Atorvastatin After Change From Rosuvastatin to Atorvastatin

Brittni Drake  1 , Derek L Grimm  1 , James Allman 2nd  1
Affiliations

Treatment Failure With Atorvastatin After Change From Rosuvastatin to Atorvastatin

Brittni Drake et al. Fed Pract. 2015 Dec.

Abstract

Lipid levels remained largely unchanged, and patients experienced few adverse events following the conversion of patients from rosuvastatin to atorvastatin therapy at the Huntington VAMC.

PubMed Disclaimer

Conflict of interest statement

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Figures

Figure 1
Figure 1
Study Population (No.) Abbreviations: ADRs, adverse drug reactions; FLP, fasting lipid profile; GI, gastrointestinal; LDL-C, low-density lipoprotein cholesterol.
See this image and copyright information in PMC

References

    1. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc. 2005;80(9):1163–1168. - PubMed
    1. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia—Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) Trials. 2006;7:35. - PMC - PubMed
    1. Park JS, Kim YJ, Choi JY, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med. 2010;25(1):27–35. - PMC - PubMed
    1. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2889–2934. - PubMed
    1. Schuster H, Barter PJ, Stender S, et al. Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statin on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004;147(4):705–713. - PubMed

LinkOut - more resources